The German biotechnology company BioNTech, which specializes in the research and production of mRNA-based therapies, became known in the wake of the Covid-19 pandemic. In 2020, the company launched the world's first approved vaccine against the SARS-CoV-2 virus. In the years that followed, BioNTech developed into a globally integrated immunotherapy company that is consistently advancing its research in the mRNA field.

Chemgineering has since made a small but important contribution to the global vaccination campaign with the transport validation of the vaccine.

The consulting mandate started in October 2020 and continued through the pandemic and beyond.

The transport validation included the creation of a master plan and a final report after extensive test planning and evaluation.

The supply network from raw materials to the finished product had to be monitored and validated seamlessly. Particularly challenging for the transportation of the vaccine and its validation is the temperature mapping from -80°C to room temperature.

Chemgineering's experience in qualification, validation and commissioning in the life science sector paid off in this and many other successful projects for well-known companies. You can find out more about our services in the areas of qualification, validation and commissioning here.

Learn more